Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer
- Focus Registrational; Therapeutic Use
- Acronyms RANGE
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 09 Feb 2023 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 21 Jan 2023 Results assessing safety of ramucirumab (Ram) for previously treated advanced gastric cancer under real-world conditions in Europe and North America, presented at the 2023 Gastrointestinal Cancers Symposium.
- 17 Jan 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.